Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05CMZ
|
||||
| Former ID |
DIB009499
|
||||
| Drug Name |
ONO-2952
|
||||
| Synonyms |
Translocator protein 18kDr (TSPO) antagonist (irritable bowel syndrome), Ono Pharmaceutical
|
||||
| Indication | Irritable bowel syndrome [ICD9: 564.1, 787.91; ICD10:A09, K58, K59.1] | Phase 2 | [1] | ||
| Company |
Ono Pharmaceutical Co Ltd
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | Peripheral-type benzodiazepine receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| HTLV-I infection | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01887002) Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D). U.S. National Institutes of Health. | ||||
| REF 2 | Anti-stress effects of ONO-2952, a novel translocator protein 18 kDa antagonist, in rats. Neuropharmacology. 2015 Jul 17;99:51-66. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.